DADavid Robert Anderson

David Robert Anderson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


David Robert Anderson has a total of 37 co-authors. Here are the top co-authors by number of shared publications:

  • Marc Alan Rodger

    Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada

    2 shared publications
  • Alexia Marrel

    Mapi Values, Lyon, France

    1 shared publication
  • Benoit Arnould

    Mapi Values, Lyon, France

    1 shared publication
  • David Zukor

    From Dalhousie University, Halifax, Nova Scotia; University of Manitoba, Winnipeg, Manitoba; Université Laval, Québec City, Québec; McGill University and Montréal University, Montréal, Québec; University of Ottawa, Ottawa, Ontario; McMaster University, Hamilton, Ontario; and University of Western Ontario, London, Ontario, Canada

    1 shared publication
  • Eric R. Bohm

    From Dalhousie University, Halifax, Nova Scotia; University of Manitoba, Winnipeg, Manitoba; Université Laval, Québec City, Québec; McGill University and Montréal University, Montréal, Québec; University of Ottawa, Ottawa, Ontario; McMaster University, Hamilton, Ontario; and University of Western Ontario, London, Ontario, Canada

    1 shared publication
  • Etienne Belzile

    From Dalhousie University, Halifax, Nova Scotia; University of Manitoba, Winnipeg, Manitoba; Université Laval, Québec City, Québec; McGill University and Montréal University, Montréal, Québec; University of Ottawa, Ottawa, Ontario; McMaster University, Hamilton, Ontario; and University of Western Ontario, London, Ontario, Canada

    1 shared publication

Latest Publications

  • Aspirin Versus Low-Molecular-Weight Heparin for Extended Venous Thromboembolism Prophylaxis After Total Hip Arthroplasty

    by David R. Anderson, Michael J. Dunbar, Eric R. Bohm, Etienne Belzile, Susan R. Kahn, David Zukor, William Fisher, Wade Gofton, Peter Gross, Stephane Pelet, et al.

    Chinese translation The role of aspirin in thromboprophylaxis after total hip arthroplasty (THA) is controversial. To compare extended prophylaxis with aspirin and dalteparin for prevention of symptomatic venous thromboembolism (VTE) after THA. Multicenter randomized, controlled trial with a noninferiority design based on a minimal clinically important difference of 2.0%. Randomization was electronically generated; patients were assigned to a treatment group through a Web-based program. Patients, physicians, study coordinators, health care team members, outcome adjudicators, and data analysts were blinded to interventions. (Current Controlled Trials: ISRCTN11902170) 12 tertiary care orthopedic referral centers in Canada. 778 patients who had elective unilateral THA between 2007 and 2010. After an initial 10 days of dalteparin prophylaxis after elective THA, patients were randomly assigned to 28 days of dalteparin (n = 400) or aspirin (n = 386). Symptomatic VTE confirmed by objective testing (primary efficacy outcome) and bleeding. Five of 398 patients (1.3%) randomly assigned to dalteparin and 1 of 380 (0.3%) randomly assigned to aspirin had VTE (absolute difference, 1.0 percentage point [95% CI, −0.5 to 2.5 percentage points]). Aspirin was noninferior (P < 0.001) but not superior (P = 0.22) to dalteparin. Clinically significant bleeding occurred in 5 patients (1.3%) receiving dalteparin and 2 (0.5%) receiving aspirin. The absolute between-group difference in a composite of all VTE and clinically significant bleeding events was 1.7 percentage points (CI, −0.3 to 3.8 percentage points; P = 0.091) in favor of aspirin. The study was halted prematurely because of difficulty with patient recruitment. Extended prophylaxis for 28 days with aspirin was noninferior to and as safe as dalteparin for the prevention of VTE after THA in patients who initially received dalteparin for 10 days. Given its low cost and greater convenience, aspirin may be considered a reasonable alternative for extended thromboprophylaxis after THA. Canadian Institutes of Health Research.


  • Open Access

    Multinational development of a questionnaire assessing patient satisfaction with anticoagulant treatment: the 'Perception of Anticoagulant Treatment Questionnaire' (PACT-Q©)

    by Martin H Prins, Alexia Marrel, Paulo Carita, David Anderson, Marie-Germaine Bousser, Harry Crijns, Silla Consoli, Benoit Arnould

    Background: The side effects and burden of anticoagulant treatments may contribute to poor compliance and consequently to treatment failure. A specific questionnaire is necessary to assess patients' needs and their perceptions of anticoagulant treatment.Methods: A conceptual model of expectation and satisfaction with anticoagulant treatment was designed by an advisory board and used to guide patient (n = 31) and clinician (n = 17) interviews in French, US English and Dutch. Patients had either atrial fibrillation (AF), deep venous thrombosis (DVT), or pulmonary embolism (PE). Following interviews, three PACT-Q language versions were developed simultaneously and further pilot-tested by 19 patients. Linguistic validations were performed for additional language versions.Results: Initial concepts were developed to cover three areas of interest: 'Treatment', 'Disease and Complications' and 'Information about disease and anticoagulant treatment'. After clinician and patient interviews, concepts were further refined into four domains and 17 concepts; test versions of the PACT-Q were then created simultaneously in three languages, each containing 27 items grouped into four domains: "Treatment Expectations" (7 items), "Convenience" (11 items), "Burden of Disease and Treatment" (2 items) and "Anticoagulant Treatment Satisfaction" (7 items). No item was deleted or added after pilot testing as patients found the PACT-Q easy to understand and appropriate in length in all languages. The PACT-Q was divided into two parts: the first part to measure the expectations and the second to measure the convenience, burden and treatment satisfaction, for evaluation prior to and after anticoagulant treatment, respectively. Eleven additional language versions were linguistically validated.Conclusion: The PACT-Q has been rigorously developed and linguistically validated. It is available in 14 languages for use with thromboembolic patients, including AF, PE and DVT patients. Its validation and psychometric properties have been tested and are presented in a separate manuscript.


  • Open Access

    Effectiveness of compression stockings to prevent the post-thrombotic syndrome (The SOX Trial and Bio-SOX biomarker substudy): a randomized controlled trial

    by the SOX Trial Investigators, Susan R Kahn, Hadia Shbaklo, Stan Shapiro, Philip S Wells, Michael J Kovacs, Marc A Rodger, David R Anderson, Jeffrey S Ginsberg, Mira Johri, et al.

    Post thrombotic syndrome (PTS) is a burdensome and costly complication of deep venous thrombosis (DVT) that develops in 20–40% of patients within 1–2 years after symptomatic DVT. Affected patients have chronic leg pain and swelling and may develop ulcers. Venous valve disruption from the thrombus itself or thrombus-associated mediators of inflammation is considered to be a key initiating event for the development of venous hypertension that often underlies PTS. As existing treatments for PTS are extremely limited, strategies that focus on preventing the development of PTS in patients with DVT are more likely to be effective and cost-effective in reducing its burden. Elastic compression stockings (ECS) could be helpful in preventing PTS; however, data on their effectiveness are scarce and conflicting.